Despite pharma growth, Merck KGaA's CDMO slowdown plays into company's overall sales decline

After posting revenue increases for six straight years, including double-digit growth in 2021 and 2022, Merck KGaA took a hard fall last year, with its global sales declining by 6% to 21 billion euros ($22.7 billion).